SEC Form 4 · accession 0001479290-18-000112
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tobin Schilke
Officer — CFO
Period of report
Nov 5, 2018
Accepted (ET)
Nov 7, 2018 · 8:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 5, 2018 | A | 18,000 | $0.00 | A | 18,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $24.96 | Nov 5, 2018 | A | 100,000 | A | — | Nov 4, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The shares subject to the Restricted Stock award shall vest in four (4) equal annual installments beginning from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan(the "Plan")) on each vesting date.
- F2The shares subject to the stock option shall vest over a period of four years commencing on November 5, 2018, with 25% vesting on the annual anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Mr. Schilke's Continuous Service (as defined in the Plan) through each such vesting date.